По вашему запросу найдено документов: 35

Страница 1 из 4

Skeletal anomalies in patients with neurofibromatosis type 1
Mustafin, R.N. (2022)
neoplasms. Therefore, the role of somatic mutations in the NF1 gene in the development of skeletal anomalies
Перспективы PARP-ингибиторов при лечении BRCA-ассоциированного рака поджелудочной железы. Обзор литературы
Prospects of PARP Inhibitors in Treatment of BRCA-Mutated Pancreatic Cancer: a Literature Review
К. В. Меньшиков, K. V. Menshikov, А. В. Султанбаев, A. V. Sultanbaev, Ш. И. Мусин, Sh. I. Musin, А. А. Измайлов, A. A. Izmailov, И. А. Меньшиков, I. A. Menshikova, Н. И. Султанбаева, N. I. Sultanbaeva, Е. В. Попова, E. V. Popova, Л. А. Хамматова, L. A. Khammatova (Креативная хирургия и онкология, №1, 2022)
Prospects of PARP Inhibitors in Treatment of BRCA-Mutated Pancreatic Cancer: a Literature Review
Особенности хирургического лечения нейрофиброматоза I типа
Questions on surgical treatment of neurofibromatosis type 1
Мустафин, Р.Н., Mustafin, R.N. (2022)
Dissecting and analyzing the Subclonal Mutations Associated with Poor Prognosis in Diffuse Glioma
Bai, Ming, Wang, Xiaolong, Zhang, Huixue, Wang, Jianjian, Lyaysan, Gaysina, Xu, Si, Tian, Kuo, Wang, Tianfeng, Li, Jie, Wang, Na, Lu, Xiaoyu, Zhang, Xiaoming, Wang, Lihua (2022)
, we first performed an integrative framework to infer the clonal status of mutations in glioblastomas
Analysis of ATL1 Gene Mutations and Clinical Features of the Disease Course in Patients with Hereditary Spastic Paraplegia
Khidiyatova, I.M., Saifullina, E.V., Karunas, A.S., Akhmetgaleyeva, A.F., Kutlubaeva, R.F., Smakova, L.A., Lobov, S.L., Polyakov, A.V., Shchagina, O.A., Kadnikova, V.A., Ryzhkova, O.P., Magzhanov, R.V. (2022)
predominant lesion of the pyramidal tract. The autosomal dominant form of SPG3A, associated with mutations
Does the c.-14C>T Mutation in the IFITM5 Gene Provide Identical Phenotypes for Osteogenesis Imperfecta Type V? Data from Russia and a Literature Review
Tyurin, Anton, Merkuryeva, Elena, Zaripova, Aliya, Markova, Tatyana, Nagornova, Tatyana, Dantsev, Ilya, Nadyrshina, Dina, Zakharova, Ekaterina, Khusainova, Rita (2022)
shown that a mutation (c.-14C>T) in the IFITM5 gene is responsible for autosomal dominant OI type V
Osteogenesis Imperfecta: Search for Mutations in Patients from the Republic of Bashkortostan (Russia)
Nadyrshina, D., Zaripova, A., Tyurin, A., Minniakhmetov, I., Zakharova, E., Khusainova, R. (2022)
in patients from Bashkortostan Republic, Russia. In total, 16 mutations in COL1A1, 11 mutations in COL1A2
Вероятная роль ретроэлементов в развитии опухоли Вильмса при хромосомных синдромах
The probable role of retroelements in the development of Wilms' tumor in chromosomal syndromes
Мустафин, Р.Н., Mustafin, R.N. (2022)
Prospects for the treatment of neurofibromatosis type 1: A review
Mustafin, R.N., Мустафин, Р.Н. (2022)
mutations in NF1 gene. Protein product of NF1 is a neurofibromin, which inhibits RAS-RAF-MEK-ERK system
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial
Kristeleit, Rebecca, Lisyanskaya, Alla, Fedenko, Alexander, Dvorkin, Mikhail, de Melo, Andreia Cristina, Shparyk, Yaroslav, Rakhmatullina, Irina, Bondarenko, Igor, Colombo, Nicoletta, Svintsitskiy, Valentyn, Biela, Luciano, Nechaeva, Marina, Lorusso, Domenica, Scambia, Giovanni, Cibula, David, Póka, Róbert, Oaknin, Ana, Safra, Tamar, Mackowiak-Matejczyk, Beata, Ma, Ling, Thomas, Daleen, Lin, Kevin K, McLachlan, Karen, Goble, Sandra, Oza, Amit M (2022)
(PARP) inhibitors to chemotherapy for the treatment of BRCA1-mutated or BRCA2-mutated ovarian carcinoma

Страница 1 из 4

Google Scholar
OpenDoar

Фасеты

Авторы
Ключевые слова
Год